86-21-64556180
cpd-service@caerulumpharma.com

CYP17

CAT # Inoa Huahana wehewehe
,

Kāhea iā mā˚ou

Ninau

Nuhou Hou

  • Loaʻa iā AstraZeneca ka hoʻoikaika kānāwai no nā lāʻau lapaʻau oncology

    Loaʻa iā AstraZeneca ka hoʻonui hoʻoponopono no...

    Ua loaʻa iā AstraZeneca kahi hoʻonui pālua no kāna kōpili oncology i ka Pōʻalua, ma hope o ka ʻae ʻana o nā regulators US a me ʻEulopa i nā hoʻouna kānāwai no kāna mau lāʻau lapaʻau, ʻo ka hana mua i ka lanakila ʻana i kēia mau lāʻau lapaʻau. ...

  • ʻO 7 ʻoi loa ma ka noiʻi lāʻau lapaʻau ma 2018

    ʻO 7 ʻoi loa i ka noiʻi lāʻau lapaʻau I...

    Ma lalo o ka piʻi nui ʻana o ka hoʻokūkū e hoʻokūkū i kahi ʻenehana paʻakikī a me ka ʻenehana, pono e hoʻomau nā ʻoihana lāʻau lapaʻau a me biotech i kā lākou papahana R&D e noho i mua ...

  • ARS-1620: He mea hoʻohiki hou no nā maʻi maʻi KRAS-mutant

    ARS-1620: He mea hoʻohiki hou no K...

    Wahi a kahi noiʻi i paʻi ʻia ma Cell, ua hoʻomohala nā mea noiʻi i kahi inhibitor kūikawā no KRASG12C i kapa ʻia ʻo ARS-1602 i hoʻoulu i ka regression tumor i nā ʻiole. "Ke hāʻawi nei kēia haʻawina i nā hōʻike vivo e hiki ke lilo i mutant KRAS ...

  • Loaʻa iā AstraZeneca ka hoʻoikaika kānāwai no nā lāʻau lapaʻau oncology

    Loaʻa iā AstraZeneca ka hoʻonui hoʻoponopono no...

    Ua loaʻa iā AstraZeneca kahi hoʻonui pālua no kāna kōpili oncology i ka Pōʻalua, ma hope o ka ʻae ʻana o nā regulators US a me ʻEulopa i nā hoʻouna kānāwai no kāna mau lāʻau lapaʻau, ʻo ka hana mua i ka lanakila ʻana i kēia mau lāʻau lapaʻau. ...

  • ʻO 7 ʻoi loa ma ka noiʻi lāʻau lapaʻau ma 2018

    ʻO 7 ʻoi loa i ka noiʻi lāʻau lapaʻau I...

    Ma lalo o ka piʻi nui ʻana o ka hoʻokūkū e hoʻokūkū i kahi ʻenehana paʻakikī a me ka ʻenehana, pono e hoʻomau nā ʻoihana lāʻau lapaʻau a me biotech i kā lākou papahana R&D e noho i mua ...

    • prev
    next
© Kuleana kope - 2015-2022 : Mālama ʻia nā Kuleana a pau.
WhatsApp kamaʻilio pūnaewele!
Close
PreviousNext
PreviousMaximize
Next